AI Without Boundaries, Painting a New Chapter: Fangzhou Jianke and Fosun Pharma Forge Strategic Partnership to Co-create a Digital-Intelligent Ecosystem for Psoriasis Management

On the occasion of World Psoriasis Day on October 29, Fangzhou Pharmaceutical (06086.HK) and Fosun Pharmaceutical held a grand signing ceremony in Shanghai to formalize their strategic partnership. Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, jointly signed the strategic cooperation agreement with Li Mei, Co-CEO of Fosun Pharmaceutical’s Domestic Marketing Platform, and Huang Jiaguo, Head of its New Retail Business Division, who both attended the event.

At the conference, both parties formally announced their close coordination and in-depth collaboration in the field of “AI + Chronic Disease Management,” joining forces to create benchmark digital-intelligence projects and further unlock the ecological value of chronic disease management. It was reported that this strategic partnership will focus on autoimmune diseases such as psoriasis as the core entry point, carrying out deep academic exchanges, science popularization, and digital marketing collaborations. By deeply integrating AI technology, the partnership aims to empower the entire chronic disease management chain—from disease awareness and intervention to long-term services—with AI capabilities, thereby supporting the high-quality development of China’s big health industry.

Image/ Fangzhou Pharmaceutical and Fosun Pharmaceutical Reach Strategic Partnership

Psoriasis is a chronic, recurrent, and inflammatory disease that requires long-term standardized management. However, traditional psoriasis management models have long been plagued by pain points such as low patient adherence, difficulties in out-of-hospital follow-up, and the lack of personalized management plans. With the deep integration of AI technology and chronic disease management, cutting-edge technologies are now capable of delivering effective services for the full disease cycle of psoriasis, including precise assessment, individualized treatment, and long-term follow-up.

Deeply integrating the core competencies of both parties to deliver superior services to patients with psoriasis is the shared direction that Fangzhou Pharmaceutical and Fosun Pharmaceutical will jointly explore. Fosun Pharmaceutical will leverage its robust commercialization platform to provide patients with Otezla® (apremilast tablets), an innovative therapeutic product for psoriasis, along with professional medical knowledge related to the condition. Meanwhile, Fangzhou Pharmaceutical will apply AI technology throughout the entire psoriasis management process by utilizing its self-developed Xingshi Medical Large Language Model and its constructed “AI+H2H (Hospital to Home) smart healthcare service ecosystem.”

Specifically, both parties will explore innovative pathways for the full-cycle management of psoriasis. Fangzhou Pharmaceutical’s AI Health Manager will provide patients with personalized rehabilitation recommendations and continuous monitoring, while its AI Medication Assistant will offer 24/7 medication consultation services. For complex medication-related issues, platforms under Fangzhou Pharmaceutical will connect patients with professional medical advisors for in-depth guidance and follow-up, ensuring the scientific rigor and safety of psoriasis management.

Li Mei, Co-CEO of Fosun Pharmaceutical’s Domestic Marketing Platform, stated, “Fangzhou Pharmaceutical and Fosun Pharmaceutical share aligned visions in the field of chronic disease management. We look forward to leveraging our innovative products and professional expertise in psoriasis, combined with Fangzhou Pharmaceutical’s new AI+H2H smart healthcare service ecosystem, to jointly build a systematic management framework for patients. On this special day dedicated to caring for psoriasis patients, we are delighted to collaborate on advancing such meaningful work for the benefit of patients.”

Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, stated, “We are delighted to enter into a strategic partnership with Fosun Pharmaceutical. This collaboration not only facilitates the sharing of our respective strengths and resources but also marks a pivotal transition in our AI strategy—from building technological capabilities to co-creating value with industry partners. We look forward to leveraging this partnership as a strong starting point to jointly establish a new paradigm for ‘AI + Psoriasis Management,’ and to extend this model to a broader range of disease areas, thereby benefiting more patients.”

Following the signing ceremony, Fangzhou Pharmaceutical announced the official launch today of the “New Horizons in AI-Enabled Psoriasis Management” Science Popularization Week (hereinafter referred to as the “Science Popularization Week”). Leveraging AI technology, the initiative delivers innovative breakthroughs in both the efficiency and quality of health science communication. On its first day of live streaming, it attracted over one million views, fully demonstrating the strong public appeal of AI-empowered health education.

Figure/Platform Showcases “AI + New Horizons in Psoriasis Management” Science Popularization Week

During this promotional week, a series of live video broadcasts will be presented to users. Notably, AI capabilities will be integrated throughout the entire process. Prior to the live streams, the platform will leverage AI technology to analyze topics of user concern and assist in the precise customization of content. During live interactions and in subsequent services, AI technology will further optimize the efficiency of information dissemination and reach, extending the immediate impact of individual science popularization sessions into personalized long-term follow-up and companion-style management.

This innovative practice has propelled health science popularization from the previous model of one-way information dissemination into a new phase characterized by user-centricity, data-driven approaches, and sustainable interaction. This initiative has not only significantly enhanced public health literacy and engagement but also provided strong support for expanding the depth and breadth of chronic disease management services by transforming health education touchpoints into continuous service entry points.

Figure: A series of psoriasis-themed science popularization and public welfare events hosted by Fangzhou Pharmaceutical

Fangzhou Pharmaceutical and Fosun Pharmaceutical will take this collaboration in the field of psoriasis as a starting point to continuously deepen their strategic synergy in areas such as digital-intelligence innovation and chronic disease management services. Building on this partnership as a cornerstone, Fangzhou Pharmaceutical is elevating its strategy to new heights, with its “AI+” ecosystem blueprint for chronic disease management rapidly unfolding. As benchmark projects like “AI+ Weight Loss” and “AI+ Psoriasis” are implemented, this innovative model will expand to cover a broader spectrum of chronic disease management, contributing robust industrial strength to the construction of a Healthy China.

Fosun Pharmaceutical is an innovation-driven, global pharmaceutical and healthcare industry group. Its directly operated businesses include pharmaceuticals, medical devices and diagnostics, and healthcare services, with coverage in the pharmaceutical distribution sector through its associates.

Fosun Pharmaceutical’s domestic marketing platform is an omni-channel, ecosystem-driven commercialization platform meticulously built to serve patients and end-users. Its business primarily covers solid tumors, hematologic malignancies, autoimmune diseases, cardiovascular conditions, digestive disorders, and chronic kidney disease.